$AEO

MCMILLAN CARY D sold $66K of AEO

MCMILLAN CARY D sold 3,617 shares of AMERICAN EAGLE OUTFITTERS INC (AEO) at $18.20 on 2026-10-06.

Original reporting
SEC EDGAR · MCMILLAN CARY D
Published Oct 7, 2026, 9:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 9:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AEO
Bearish
medium confidence
Mentioned
$AEO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEOBearishLow
01

Why it matters

The filing discloses a director's sale of 3,617 shares, valued at $65,829, leaving no remaining holdings.

02

Market read

A modest insider sale with limited impact; may cause slight short-term pressure but unlikely to move the stock materially.

03

What to watch

Director may be diversifying holdings; small size reduces significance.

Relevance 3/10Novelty 3/10Timing: same-day

Background

SEC Form 4 filing reports an insider transaction for American Eagle Outfitters.

Company-level read

Ticker impact

$AEOBearishMedium confidence
Context

Director sold 3,617 shares for $65,829, reducing holdings to zero.

Expected impact

likely slight downward pressure as market prices in the insider sell

Evidence & confidence

Director's sale of $66K is modest, but signals limited confidence; size is too small for major move

Market effects

Retail apparel sector may see minor negative sentiment from insider sell.

US market impact limited to AEO shareholders.

Limited global relevance; effect confined to the company.

Counterpoint

Sale could be routine tax or estate planning, not a lack of confidence.

Key entities

  • American Eagle Outfitters Inc

    US-listed retailer (ticker AEO) whose director sold shares.

  • Cary D. McMillan

    Director of American Eagle Outfitters who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AEOMed

BMO raises American Eagle Outfitters stock price target on Aerie momentum

BMO Capital raised its price target on American Eagle Outfitters (NYSE:AEO) to $20 from $18, citing strong Aerie brand momentum and improved women's bottoms sales. The stock trades at $17.41 with a P/E ratio of 8.93. BMO expects upside to Q4 gross margin guidance due to lower tariff rates. AEO reported Q2 earnings of $0.79 per share on $1.38 billion revenue, beating estimates. TD Cowen cut its target to $16, while UBS lowered its target to $27 but maintained a Buy rating.

$AEOHighAI 8/10

Earnings Guidance Lift Could Change The Bull Case For American Eagle Outfitters (AEO)?

American Eagle Outfitters (AEO) reported Q2 2026 sales of $1.38B, net income of $134.08M, and EPS of $0.80. The company issued Q3 and full-year 2026 operating income guidance of $110M-$115M and $540M-$550M, respectively. Analysts highlight execution around inventory, markdowns, and digital productivity as key catalysts, while noting risks from consumer caution and cost pressures. The company declared a quarterly dividend of $0.125 per share.

$AEOMedAI 8/10

American Eagle Goes on Sale: Is It Time to Buy?

American Eagle reported Q2 revenue of $1.4B, up 8%, beating expectations. Aerie and OFFLINE segments drove growth, while the core brand faced challenges. Margins were impacted by tariff refunds and markdowns. Analysts trimmed price targets, but the consensus suggests 35% upside. Institutional investors own 98% of the float, showing bullish signs. The core brand's turnaround is a key risk.

$AAPLMed

Apple, Compass Pathways, Aritzia and more analyst calls of the week

Dell shares rose 11% to a record high after RBC initiated coverage with an Outperform rating and $640 target, citing strong AI and PC demand. Apple shares gained 3.1% after unveiling its first foldable iPhone, the iPhone Duo, priced at $1,999 and above. AstraZeneca's shares remained flat despite mixed analyst views on its drug tozorakimab. Compass Pathways shares climbed 4% on positive Phase III study data for its psilocybin treatment.